Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease

Movement Disorders

Volumn 32, Issue 10, 2017, Pages 1401-1408

  Trezzi, Jean Pierre ^a,b   Galozzi, Sara ^c   Jaeger, Christian ^a   Barkovits, Katalin ^c   Brockmann, Kathrin ^d,e   Maetzler, Walter ^d,e   Berg, Daniela ^d,e,f   Marcus, Katrin ^c   Betsou, Fay ^b   Hiller, Karsten ^a,g,h   Mollenhauer, Brit ^i,j  

^a UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^b INTEGRATED BIOBANK OF LUXEMBOURG   (Luxembourg)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^f UNIVERSITY OF KIEL   (Germany)

^g TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^h HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

ⁱ Paracelsus Elena Klinik   (Germany)

^j UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

more..

Author keywords

biomarker; CSF; logistic regression; metabolomics; Parkinson's disease

Indexed keywords

ALPHA HYDROXYBUTYRIC ACID; ASCORBIC ACID; BIOLOGICAL MARKER; CARBONIC ACID; DEHYDROASCORBIC ACID; ENDOPLASMIC RETICULUM GOLGI INTERMEDIATE COMPARTMENT PROTEIN 53; FRUCTOSE; GLUCOSE; GLYCERIC ACID; HEMOGLOBIN; IMMUNOGLOBULIN G; LAURIC ACID; MANNOSE; MANNOSE BINDING LECTIN; MARKER; THREONIC ACID; UNCLASSIFIED DRUG; UREA; BUTYRIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; MACHINE LEARNING; MALE; MASS SPECTROMETRY; METABOLOMICS; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; SENSITIVITY AND SPECIFICITY; CASE CONTROL STUDY; MASS FRAGMENTOGRAPHY; MIDDLE AGED; PROCEDURES; STATISTICAL MODEL;

ADULT; AGED; BIOMARKERS; BUTYRATES; CASE-CONTROL STUDIES; COHORT STUDIES; DEHYDROASCORBIC ACID; FEMALE; FRUCTOSE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LOGISTIC MODELS; MALE; MANNOSE; METABOLOMICS; MIDDLE AGED; PARKINSON DISEASE;

EID: 85028329332     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.27132     Document Type: Article

References (40)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55(3):181-184.
2. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014;83(5):406-412.
3. Ahmed SS, Santosh W, Kumar S, Christlet HT. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci 2009;16:63.
4. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008;131(pt 2):389-396.
5. Devic I, Hwang H, Edgar JS, et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011;134(Pt 7):e178.
6. Michell AW, Mosedale D, Grainger DJ, Barker RA. Metabolomic analysis of urine and serum in Parkinson's disease. Metabolomics 2008;4(3):191-201.
7. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10(3):230-240.
8. Qiang JK, Wong YC, Siderowf A, et al. Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol 2013;74(1):119-127.
9. van Rooden SM, Colas F, Martinez-Martin P, et al. Clinical subtypes of Parkinson's disease. Mov Disord 2011;26(1):51-58.
10. Mollenhauer B, Trautmann E, Sixel-Doring F, et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 2013;81(14):1226-1234.
11. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18(7):738-750.
12. Mollenhauer B, Zimmermann J, Sixel-Döring F, et al. Monitoring of thirty marker candidates in early Parkinson's disease as progression markers. Neurology 2016;87(2):168-177.
13. Brockmann K, Groger A, Di Santo A, et al. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011;26(13):2335-2342.
14. Brockmann K, Srulijes K, Hauser AK, et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011;77(3):276-280.
15. Maetzler W, Karam M, Berger MF, et al. Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson's disease. J Neural Transm 2015;122(3):419-425.
16. Brockmann K, Schulte C, Deuschle C, et al. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. Parkinsonism Relat Disord 2015;21(12):1427-1434.
17. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 2010;4(5):683-699.
18. Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurology 2013;70(10):1277-1287.
19. Maetzler W, Schmid SP, Wurster I, et al. Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord 2011;26(1):176-181.
20. Lehmann S, Guadagni F, Moore H, et al. Standard preanalytical coding for biospecimens: review and implementation of the Sample PREanalytical Code (SPREC). Biopreserv Biobank 2012;10(4):366-374.
21. Rosenling T, Slim CL, Christin C, et al. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J Proteom Res 2009;8(12):5511-5522.
22. Rosenling T, Stoop MP, Smolinska A, et al. The impact of delayed storage on the measured proteome and metabolome of human cerebrospinal fluid. Clin Chem 2011;57(12):1703-1711.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995:289-300.
24. Ruxton GD. The unequal variance t-test is an underused alternative to Student's t-test and the Mann–Whitney U test. Behav Ecol 2006;17(4):688-690.
25. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010;37(3):510-518.
26. Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol 2013;106-107:17-32.
27. Huang J, Agus DB, Winfree CJ, et al. Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc Natl Acad Sci U S A 2001;98(20):11720-11724.
28. Barabas J, Nagy E, Degrell I. Ascorbic acid in cerebrospinal fluid - a possible protection against free radicals in the brain. Arch Gerontol Geriatr 1995;21(1):43-48.
29. Thomas M, Hughes R. A relationship between ascorbic acid and threonic acid in guinea-pigs. Food Chem Toxicol 1983;21(4):449-452.
30. Izumi Y, Zorumski CF. Glial-neuronal interactions underlying fructose utilization in rat hippocampal slices. Neuroscience 2009;161(3):847-854.
31. Mazzio E, Soliman KF. The role of glycolysis and gluconeogenesis in the cytoprotection of neuroblastoma cells against 1-methyl 4-phenylpyridinium ion toxicity. Neurotoxicology 2003;24(1):137-147.
32. Shental-Bechor D, Levy Y. Effect of glycosylation on protein folding: a close look at thermodynamic stabilization. Proc Natl Acad Sci U S A 2008;105(24):8256-8261.
33. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014;18(1):1-14.
34. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984;101(4):527-537.
35. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992;15(12):1835-1843.
36. Vicente Miranda H, Outeiro TF. The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol 2010;221(1):13-25.
37. Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 2005;64(9):816-830.
38. Kwok JY, Augst RM, Yu DY, Singh KK. Sensitive CSF ELISAs for the detection of MBL, MASP-2 and functional MBL/MASP-2. J Neurosci Methods 2012;209(1):255-257.
39. Sjolander A, Minthon L, Nuytinck L, Vanmechelen E, Blennow K, Nilsson S. Functional mannose-binding lectin haplotype variants are associated with Alzheimer's disease. J Alzheimers Dis 2013;35(1):121-127.
40. Trupp M, Jonsson P, Ohrfelt A, et al. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. J Parkinsons Dis 2014;4(3):549-560.